CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $3.91B, above the global median of $1.15B
- FinancialsAltman Z-Score 3.97: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
4.81%Above 5Y avg (3.71%)
Annual Rate
CNY 1.43Paid annual
Payout Ratio
49.8%Sustainable
Payback Period
20.5 yr
Last Ex-Dividend
Jun 16, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
26.39BCNY3.91B · vs all stocks (USD)
Trailing P/E
13.70xRevenue (TTM)
11.71BCNY1.74B · vs all stocks (USD)
Profit Margin
16.77%Beta
0.1380xvs all stocks
52-Week Change
-26.60%vs all stocks
Market Capitalization
26.39BCNY3.91B · vs all stocks (USD)
Enterprise Value
21.41BCNY3.18B · vs all stocks (USD)
Trailing P/E
13.70xForward P/E
12.06xPrice to Sales (TTM)
2.30xPrice to Book (MRQ)
1.85xEnterprise to Revenue
1.83xEnterprise to EBITDA
6.89xGross Margin
65.87%Profit Margin
16.77%Operating Margin
29.10%Return on Assets (TTM)
6.59%Return on Equity (TTM)
15.06%Revenue (TTM)
11.71BCNY1.74B · vs all stocks (USD)
Revenue per Share (TTM)
13.15CNYUpdated Aug 18, 2026Quarterly Revenue Growth
-9.70%Gross Profit (TTM)
7.71BCNY1.14B · vs all stocks (USD)
EBITDA (TTM)
3.21BCNY475.83M · vs all stocks (USD)
Net Income (TTM)
1.96BCNY291.18M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-9.40%Operating Cash Flow (TTM)
3.24BCNY480.17M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.92BCNY284.37M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.43CNYUpdated Aug 18, 2026Trailing Annual Dividend Yield
4.81%vs all stocks
5-Year Average Dividend Yield
3.71%vs all stocks
Payout Ratio
49.77%Minority Interest (Equity)
1.66BCNYFY2025 · Dec 31, 2025Revenue
12.02BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
4.10BCNYFY2025 · Dec 31, 2025Gross Profit
7.92BCNYFY2025 · Dec 31, 2025Operating Income
2.77BCNY411.52M · vs all stocks (USD)
Pre-tax Income
2.86BCNYFY2025 · Dec 31, 2025Income Tax Expense
451.01MCNYFY2025 · Dec 31, 2025Net Income
2.41BCNYFY2025 · Dec 31, 2025EBIT
2.92BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
3.59BCNYFY2025 · Dec 31, 2025Research & Development
937.95MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
3.30BCNYFY2025 · Dec 31, 2025Other Operating Expenses
171.70MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
297.58MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
57.21MCNYFY2025 · Dec 31, 2025EPS (Basic)
2.27CNYFY2025 · Dec 31, 2025EPS (Diluted)
2.27CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
891.30MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
891.30MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
2.41BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-387.79MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
2.59BCNYFY2025 · Dec 31, 2025Free Cash Flow
2.01BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
7.44BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
2.41BCNYFY2025 · Dec 31, 2025Other Non-cash Items
126.16MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-279.10MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
327.50MCNYFY2025 · Dec 31, 2025Capital Expenditures
-572.15MCNYFY2025 · Dec 31, 2025Purchase of Investments
-8.93BCNYFY2025 · Dec 31, 2025Sale of Investments
7.60BCNYFY2025 · Dec 31, 2025Other Investing Activity
-1.86BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.76BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
3.91BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-4.84BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.03BCNYFY2025 · Dec 31, 2025Other Financing Charges
-595.09MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.56BCNYFY2025 · Dec 31, 2025Shares Outstanding
887.91MSharesUpdated Aug 18, 2026Float Shares
460.63MSharesUpdated Aug 18, 2026% Held by Insiders
44.90%vs all stocks
% Held by Institutions
6.18%vs all stocks
Total Cash (MRQ)
9.97BCNY1.48B · vs all stocks (USD)
Total Cash per Share (MRQ)
11.23CNYUpdated Aug 18, 2026Total Debt (MRQ)
2.97BCNY439.83M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1903xCurrent Ratio (MRQ)
1.96xBook Value per Share (MRQ)
16.34CNYUpdated Aug 18, 2026Total Assets
23.99BCNY3.56B · vs all stocks (USD)
Total Current Assets
16.12BCNYFY2025 · Dec 31, 2025Total Liabilities
8.44BCNYFY2025 · Dec 31, 2025Total Non-current Assets
7.87BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.22BCNYFY2025 · Dec 31, 2025Total Current Liabilities
7.22BCNYFY2025 · Dec 31, 2025Cash
9.19BCNYFY2025 · Dec 31, 2025Cash Equivalents
114.88MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
9.31BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.34BCNYFY2025 · Dec 31, 2025Accounts Receivable
2.25BCNYFY2025 · Dec 31, 2025Inventory
1.56BCNYFY2025 · Dec 31, 2025Accounts Payable
1.32BCNYFY2025 · Dec 31, 2025Short-term Debt
2.29BCNYFY2025 · Dec 31, 2025Other Current Liabilities
6.80MCNYFY2025 · Dec 31, 2025Long-term Debt
766.68MCNYFY2025 · Dec 31, 2025Common Stock (Book)
887.91MCNYFY2025 · Dec 31, 2025Retained Earnings
12.74BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
15.55BCNY2.31B · vs all stocks (USD)
52-Week Low
27.67CNYUpdated Aug 18, 202652-Week High
42.58CNYUpdated Aug 18, 202652-Week Change
-26.60%vs all stocks
Beta
0.1380xvs all stocks
50-Day MA
30.43CNYUpdated Aug 18, 2026200-Day MA
33.45CNYUpdated Aug 18, 2026Avg 10-Day Volume
6.58MSharesUpdated Aug 18, 2026Avg 30-Day Volume
6.92MSharesUpdated Aug 18, 2026Diluted EPS (TTM)
2.21CNYUpdated Aug 18, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.97: safe zoneNotable
Altman Z-Score: 3.97
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $3.91B, above the global median of $1.15BNotable
Market cap (USD): 3,913,429,546.393Global Median: 1,146,734,693.424
Revenue is $1.74B, above the global median of $520.53MNotable
Revenue (USD): 1,736,702,509.466Global Median: 520,528,949.311
Levered free cash flow is $284.37M, above the global median of $16.24MNotable
Levered free cash flow (USD): 284,374,651.034Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Dyne Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Xiamen Amoytop Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Duality Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Huahai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Catalyst Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Apeloa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
Enliven Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
J.B. Chemicals & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Sun Pharmaceutical Industries Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Tapdi Oksijen Özel Sağlik Hizmetleri A.Ş.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Friedrich Vorwerk Group SE
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities